Michele Simbolo

List of Publications by Year
in descending order

83 papers	5,656 citations	186265 28 h-index	98798 67 g-index
86 all docs	86 docs citations	86 times ranked	11078 citing authors

#	Article	IF	Citations
1	Pan-cancer analysis of whole genomes. Nature, 2020, 578, 82-93.	27.8	1,966
2	Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 2017, 543, 65-71.	27.8	716
3	Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nature Genetics, 2013, 45, 1470-1473.	21.4	564
4	Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. Journal of Hepatology, 2018, 68, 959-969.	3.7	254
5	DNA Qualification Workflow for Next Generation Sequencing of Histopathological Samples. PLoS ONE, 2013, 8, e62692.	2.5	209
6	Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin‐remodelling genes as major players and a prognostic role for *TERT*, *RB1*, *MEN1* and *KMT2D*. Journal of Pathology, 2017, 241, 488-500.	4.5	179
7	Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget, 2014, 5, 2839-2852.	1.8	171
8	A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics. Cancer Discovery, 2015, 5, 1296-1313.	9.4	145
9	MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology, 2018, 154, 1066-1079.e5.	1.3	94
10	Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients. Annals of Surgical Oncology, 2016, 23, 1699-1707.	1.5	76
11	Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. Journal of Thoracic Oncology, 2018, 13, 1692-1704.	1.1	74
12	Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. Journal of Thoracic Oncology, 2019, 14, 1651-1661.	1.1	73
13	BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. Oncotarget, 2016, 7, 1076-1083.	1.8	68
14	High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 73-78.	2.8	66
15	Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 567-577.	2.8	64
16	High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers. Gastric Cancer, 2014, 17, 442-449.	5.3	52
17	Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex. Carcinogenesis, 2018, 39, 971-980.	2.8	48
18	Next-Generation Histopathologic Diagnosis: A Lesson From a Hepatic Carcinosarcoma. Journal of Clinical Oncology, 2014, 32, e63-e66.	1.6	47

#	Article	IF	Citations
19	Evaluation of Correlations between Genetic Variants and High-Resolution Computed Tomography Patterns in Idiopathic Pulmonary Fibrosis. Diagnostics, 2021, 11, 762.	2.6	47
20	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. Scientific Reports, 2017, 7, 43013.	3.3	44
21	Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study. Cancers, 2020, 12, 2283.	3.7	41
22	Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 709-717.	2.8	40
23	Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. Scientific Reports, 2018, 8, 7119.	3.3	39
24	Frequent <i>NRG1</i> fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression. Oncotarget, 2018, 9, 9661-9671.	1.8	36
25	Ampulla of Vater Carcinoma. Annals of Surgery, 2018, 267, 149-156.	4.2	35
26	Reporting Tumor Molecular Heterogeneity in Histopathological Diagnosis. PLoS ONE, 2014, 9, e104979.	2.5	35
27	Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas. Journal of Pathology, 2019, 247, 123-134.	4.5	32
28	Next-generation sequencing for genetic testing of familial colorectal cancer syndromes. Hereditary Cancer in Clinical Practice, 2015, 13, 18.	1.5	31
29	Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease. Scientific Reports, 2019, 9, 12286.	3.3	27
30	Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities. Frontiers in Oncology, 2021, 11, 650293.	2.8	26
31	Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer. Annals of Oncology, 2017, 28, 1243-1249.	1.2	25
32	Exosomal miRNA signatures of pancreatic lesions. BMC Gastroenterology, 2020, 20, 137.	2.0	25
33	Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment. Cancers, 2019, 11, 1279.	3.7	23
34	Diffuse gliomas in patients aged 55â€‰years or over: A suggestion for <i>IDH</i> mutation testing. Neuropathology, 2020, 40, 68-74.	1.2	23
35	Collapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell Secretome. Cancer Immunology Research, 2019, 7, 12-28.	3.4	21
36	Molecular Profiling of 22 Primary Atypical Meningiomas Shows the Prognostic Significance of 18q Heterozygous Loss and CDKN2A/B Homozygous Deletion on Recurrence-Free Survival. Cancers, 2021, 13, 903.	3.7	20

#	Article	IF	Citations
37	Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. ESMO Open, 2021, 6, 100032.	4.5	19
38	Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer. Targeted Oncology, 2018, 13, 649-655.	3.6	18
39	Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis. Scientific Reports, 2016, 6, 22982.	3.3	16
40	Centrosome Linker–induced Tetraploid Segregation Errors Link Rhabdoid Phenotypes and Lethal Colorectal Cancers. Molecular Cancer Research, 2018, 16, 1385-1395.	3.4	13
41	Molecular characterization of extrahepatic cholangiocarcinoma: perihilar and distal tumors display divergent genomic and transcriptomic profiles. Expert Opinion on Therapeutic Targets, 2021, 25, 1095-1105.	3.4	13
42	H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 987-996.	2.8	12
43	Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma. Pancreas, 2019, 48, 70-76.	1.1	11
44	Combined adenocarcinoma–atypical carcinoid of the lung. Targeted Next-Generation Sequencing (NGS) suggests a monoclonal origin of the two components. Diagnostic Histopathology, 2018, 24, 120-123.	0.4	10
45	Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification?. Hpb, 2019, 21, 1648-1655.	0.3	10
46	Gene Expression Profiling of Pancreas Neuroendocrine Tumors with Different Ki67-Based Grades. Cancers, 2021, 13, 2054.	3.7	10
47	IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation. Acta Neuropathologica Communications, 2021, 9, 200.	5.2	10
48	Multigene mutational profiling of biliary tract cancer is related to the pattern of recurrence in surgically resected patients. Updates in Surgery, 2020, 72, 119-128.	2.0	9
49	Glioblastoma with tumor–to–tumor metastasis from lung adenocarcinoma. Neuropathology, 2019, 39, 474-478.	1.2	7
50	Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas. Human Pathology, 2022, 128, 124-133.	2.0	6
51	New genomic landscapes and therapeutic targets for biliary tract cancers. Frontiers in Bioscience - Landmark, 2016, 21, 707-718.	3.0	5
52	Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. Journal of Clinical Medicine, 2021, 10, 1741.	2.4	5
53	OA06.06 Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC). Journal of Thoracic Oncology, 2017, 12, S266-S267.	1.1	4
54	Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. Breast, 2020, 50, 56-63.	2.2	4

#	Article	IF	Citations
55	Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned. Cells, 2021, 10, 2685.	4.1	4
56	Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance. Biomedicines, 2022, 10, 277.	3.2	4
57	Molecular and Clinical Insights in Malignant Brenner Tumor of the Testis With Liver Metastases:A Case Report. Frontiers in Oncology, 2021, 11, 663489.	2.8	3
58	Juvenile polyposis diagnosed with an integrated histological, immunohistochemical and molecular approach identifying new SMAD4 pathogenic variants. Familial Cancer, 2022, 21, 441-451.	1.9	3
59	Undifferentiated Sarcomatoid Carcinoma of the Pancreas: From Histology and Molecular Pathology to Precision Oncology. International Journal of Molecular Sciences, 2022, 23, 1283.	4.1	3
60	Intraventricular Meningiomas: Clinical-Pathological and Genetic Features of a Monocentric Series. Current Oncology, 2022, 29, 178-185.	2.2	3
61	Exploring the molecular and biological background of lung neuroendocrine tumours. Journal of Thoracic Disease, 2019, 11, S1194-S1198.	1.4	2
62	Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma. Anti-Cancer Drugs, 2015, 26, 469-473.	1.4	1
63	Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models. Annals of Oncology, 2018, 29, viii665.	1.2	1
64	ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance. Pathology Research and Practice, 2018, 214, 1675-1680.	2.3	1
65	Clinical-Pathological, Immunohistochemical, and Genetic Characterization of a Series of Posterior Pituitary Tumors. Journal of Neuropathology and Experimental Neurology, 2021, 80, 45-51.	1.7	1
66	Next-generation targeted sequencing (NGTS) investigating CDK4 as a prognostic driver in pure invasive lobular breast carcinoma (ILC): Preliminary results in early-stage patients (pts) stratified according to a validated clinico-pathological model.. Journal of Clinical Oncology, 2018, 36, 542-542.	1.6	1
67	Metastasis of lung carcinoid in the thyroid gland after 18 years: it is never too late. A case report and review of the literature. Pathologica, 2022, 114, 164-169.	3.4	1
68	Molecular Portrait of Resected Gastric Cancer (Rgc) with Next Generation Sequencing (Ngs) According to a Clinical Biological Risk Model Considering Fhit, Apc and Her-2 Overexpression. Annals of Oncology, 2014, 25, iv219.	1.2	0
69	Detection of EGFR alterations in circulating tumor DNA of non-small cell lung cancer by digital PCR and Next Generation Sequencing. Annals of Oncology, 2015, 26, vi79.	1.2	0
70	483 The Concept of Perihilar Cholangiocarcinoma Is Still Valid? Analysis of Clinicopathological Features and Mutational Genes Profiling in a Series of 56 Cases. Gastroenterology, 2015, 148, S-1111.	1.3	0
71	Potentially druggable molecular and immune-related pathways drive the prognosis of resected squamous cell lung carcinoma (R-SqCLC): preliminary results of prognostic outliers according to a clinicopathological model. Annals of Oncology, 2016, 27, iv7.	1.2	0
72	HSP-90 Inhibition is a Promising Therapeutic Strategy in Cholangiocarcinoma and MIR-21 may Serve as a Biomarker of Sensitivity. Journal of Hepatology, 2016, 64, S559.	3.7	0

#	Article	IF	Citations
73	Results of an integrated multi-platforms analysis in squamous cell lung carcinoma (SqCLC) revealed PI3K/RICTOR-mTORC2 axis as a potential prognostic biomarker and druggable target. Annals of Oncology, 2017, 28, vi57.	1.2	0
74	Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations. Annals of Oncology, 2018, 29, viii511-viii512.	1.2	0
75	P2.04-12 A Genomic Signature [JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2] Predicts Baseline Resistance to Nivolumab in Advanced NSCLC.. Journal of Thoracic Oncology, 2018, 13, S734-S735.	1.1	0
76	Validation of a tumour mutational burden workflow on routine histological samples of colorectal cancer and assessment of a cohort with synchronous hepatic metastases. Annals of Oncology, 2019, 30, v574.	1.2	0
77	Comparative Lesions Analysis Through a Targeted Sequencing Approach. Journal of Visualized Experiments, 2019, , .	0.3	0
78	P2.04-51 A 6-Gene Immune Genomic Signature (IGS) Predicts Resistance to Nivolumab [NIV] in Advanced Pretreated NSCLC: Results of PRINCiPe Trial. Journal of Thoracic Oncology, 2019, 14, S728.	1.1	0
79	30P Assessing the potential role of RICTOR expression as predictive factor of response to PI3K/mTOR pathway inhibitors in preclinical models of squamous cell lung cancer. Annals of Oncology, 2020, 31, S10.	1.2	0
80	Molecular Biology of Neuroendocrine Tumors. , 2021, , 37-53.		0
81	Abstract 3287: Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT. , 2011, , .		0
82	Abstract 1069: MiR-21 may serve as a predictive biomarker of response in the assessment of efficacy of HSP-90 inhibition in gastrointestinal (GI) cancers. , 2016, , .		0
83	Co-existance of KRAS and LKB1 mutation as predictor of resistance to Erlotinib: Customized next-generation sequencing (NGS) of TAILOR trial.. Journal of Clinical Oncology, 2017, 35, e20631-e20631.	1.6	0